Literature DB >> 31372725

Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment-Oriented Lymph Node Resection.

Carlos Gustavo Rivera-Robledo1, David Velázquez-Fernández2, Juan Pablo Pantoja2, Mauricio Sierra2, Bernardo Pérez-Enriquez3, Raul Rivera-Moscoso3, Mónica Chapa4, Miguel F Herrera2.   

Abstract

INTRODUCTION: Recurrence of papillary thyroid carcinoma after initial treatment is challenging. Surgical reintervention is recommended, but cure after surgery in uncertain and surgical morbidity may be high. This study evaluates the effect of compartment-oriented lymph node dissection (LND) on clinical and biochemical cure rate as well as the related complications. PATIENTS AND METHODS: All patients who underwent LND for recurrent papillary thyroid carcinoma between 2000 and 2015 were included. Demography, the extent of the initial surgery, usage of 131I, the pattern of recurrence, diagnosis, details of the surgical reintervention, histological findings, surgical morbidity, and clinical and biochemical outcomes were analyzed.
RESULTS: There were 11 (12.7%) males and 75 (87.2%) females with a mean age of 42.8 ± 14.6 years. Seventy-seven patients had undergone total thyroidectomy and in 67 (77.9%) some type of LN resection. In 76 (88.3%), 131I was administered after the initial surgery. We localized suspicious lymph nodes by US in all patients, and metastases were documented before surgery by FNA in 63. Seven (8.13%) patients underwent central LND, 63 (73.2%) lateral LND and 16 (18.6%) both, central and lateral LND. Major complications occurred in 6 patients (6.9%). Sixty-two (72.0%) patients received 131I after surgery. A second surgical re-exploration was performed in 30 (34.8%) patients, and 7 patients required 3 or more additional LND. In a mean follow-up of 59.4 ± 39 months, 51 (59.3%) patients are clinically, radiologically and biochemically free of disease.
CONCLUSIONS: In this series, compartment-oriented lymph node resection of recurrent papillary thyroid carcinoma leads to a final clinical and biochemical disease-free status of 59.3% with 6.9% of major complications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31372725     DOI: 10.1007/s00268-019-05094-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  39 in total

Review 1.  Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008.

Authors:  Nan Li; Xianglin L Du; Lorraine R Reitzel; Li Xu; Erich M Sturgis
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

2.  Risk Factors for Re-recurrence After First Reoperative Surgery for Locoregional Recurrent/Persistent Papillary Thyroid Carcinoma.

Authors:  Hwan Seo Lee; Jong-Lyel Roh; Gyungyup Gong; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

Review 3.  Distant metastases from thyroid and parathyroid cancer.

Authors:  A R Shaha; A Ferlito; A Rinaldo
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2001 Jul-Aug       Impact factor: 1.538

4.  Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.

Authors:  Gary L Clayman; Garima Agarwal; Beth S Edeiken; Steven G Waguespack; Dianna B Roberts; Steven I Sherman
Journal:  Thyroid       Date:  2011-12       Impact factor: 6.568

5.  Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors.

Authors:  M F Herrera; C M López-Graniel; J Saldaña; A Gamboa-Domínguez; Y Richaud-Patín; F Vargas-Vorackova; A Angeles-Angeles; L Llorente; C Castillo; B Pérez; R Rivera; O González; J Rull
Journal:  World J Surg       Date:  1996-01       Impact factor: 3.352

6.  Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients.

Authors:  David Lesnik; Mary Elizabeth Cunnane; David Zurakowski; Gul Ozbilen Acar; Cenk Ecevit; Alasdair Mace; Dipti Kamani; Gregory W Randolph
Journal:  Head Neck       Date:  2013-04-02       Impact factor: 3.147

Review 7.  Update in utility of secondary node dissection for papillary thyroid cancer.

Authors:  David L Steward
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958

8.  Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer.

Authors:  S G A de Meer; M Dauwan; B de Keizer; G D Valk; I H M Borel Rinkes; M R Vriens
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

9.  Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Koon Yat Wan
Journal:  Ann Surg Oncol       Date:  2012-09-07       Impact factor: 5.344

10.  Pattern, predictors, and recurrence of cervical lymph node metastases in papillary thyroid cancer.

Authors:  Lan Shi; Haiping Song; Huiping Zhu; Dapeng Li; Ning Zhang
Journal:  Contemp Oncol (Pozn)       Date:  2013-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.